PMA device
BSD-500 Hyperthermia System
Pyrexar Medical, Inc. · System, Rf/Microwave Hyperthermia, Cancer Treatment (LOC, Class III) · First FDA decision Oct 8, 2003, newest Jan 20, 2004Tumor ablation
Last checked: Nov 20, 2026Source: FDA, CMS, ClinicalTrials.gov, PubMed
FDA decisions
2
PMA pathway
Device trials
0
Naming "BSD-500"
MAUDE reports
0
Brand "BSD-500", since 2015
PubMed studies
1
Mentioning "BSD-500"
AI summary across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, MAUDE and PubMed data on this page, plus web searches for payment facts.
Product review deck
A slide deck reviewing BSD-500 Hyperthermia System
About ten slides on the technology, clinical evidence, regulatory history and commercialization, built with AI from the data on this page and web research, with sources. Download it as PowerPoint to edit or as PDF to share.
- Executive summary and key facts
- Technology
- Clinical evidence and trials
- Regulatory history and safety
- Reimbursement, market and competition
- Risks, outlook and sources
AI-written from public data and may contain mistakes. Check each fact against its source before relying on it. Not investment, legal, reimbursement or medical advice.
FDA decisions
The newest 2 of 2 decisions filed under this name.
- BSD-500 HYPERTHERMIA SYSTEMPMA supplement
P820088-S017 · Decided Jan 20, 2004 · 116 days after receipt · Normal 180 Day Track
Device type: System, rf/microwave hyperthermia, cancer treatment (LOC) · Radiology & Imaging
- BSD-500 HYPERTHERMIA SYSTEMPMA supplement
P820088-S016 · Decided Oct 8, 2003 · 170 days after receipt · Normal 180 Day Track
Device type: System, rf/microwave hyperthermia, cancer treatment (LOC) · Radiology & Imaging
Medicare coverage
National and local coverage documents whose titles match this device or its device type. Payment add-ons (NTAP, pass-through, TCET) and likely codes are covered in the summary above.
- Hyperthermia for Treatment of CancerNational determinationOn the books110.1Updated Apr 17, 2020
- Autologous Cellular Immunotherapy Treatment of Metastatic Prostate CancerNational analysisReview closedCAG-00422NUpdated Nov 19, 2026
- Abarelix for the Treatment of Prostate CancerNational analysisReview closedCAG-00238NUpdated Sep 15, 2026
- Superficial Radiation Therapy (SRT) for the Treatment of Nonmelanoma Skin Cancers (NMSC)Local determinationIn effectL40168Wellpoint FederalUpdated Jul 14, 2026
- Superficial Radiation Therapy (SRT) for the Treatment of Nonmelanoma Skin Cancers (NMSC)Local determinationIn effectL40179CGS Administrators, LLCUpdated Apr 17, 2026
- Superficial Radiation Therapy (SRT) for the Treatment of Nonmelanoma Skin Cancers (NMSC)Local determinationIn effectL40193WPS Insurance CorporationUpdated Mar 12, 2026
- Superficial Radiation Therapy (SRT) for the Treatment of Nonmelanoma Skin Cancers (NMSC)Local determinationIn effectL40189Palmetto GBAUpdated Mar 11, 2026
- Superficial Radiation Therapy (SRT) for the Treatment of Nonmelanoma Skin Cancers (NMSC)Local determinationIn effectL40176Noridian Healthcare Solutions, LLCUpdated Mar 10, 2026
Clinical trials
Device studies on ClinicalTrials.gov that name "BSD-500", any status and sponsor, newest update first.
No registered device study names "BSD-500".
Adverse event reports (MAUDE)
Reports received since 2015 naming the brand "BSD-500", and for the whole product code for context.
This brand
0 reports: 0 malfunction, 0 injury, 0 death
Whole product code LOC
0 reports: 0 malfunction, 0 injury, 0 death
Newest reports for this brand
No MAUDE reports name this brand.
Recalls
From FDA's recall database. FDA lists each recalled product separately, so one recall can appear several times. A recall is often a correction or a labeling change, not a removal from the market.
No recall in FDA's data is linked to these FDA numbers.
Published research
The most relevant PubMed records for "BSD-500"[tiab]. The summary above synthesizes these.
- Design and base validation of a small-animal hyperthermia applicator.
Kahlert B, Rückert M, Sengedorj A, et al. · Phys Med Biol · 2026Validation Study
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.